- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04506632
Burden for STaff Working in the NHS (COST-NHS)
COST-NHS: COvid Burden in STaff Working in the NHS: A Study to Assess the Mental Health Burden of the COVID-19 Pandemic on NHS Healthcare Staff
The COVID-19 crisis began in China in December 2019 and was declared a pandemic by the World Health Organisation on March 11th 2020. The pandemic has changed the way that clinicians interact with and treat patients overnight. Staff within the NHS will be under high levels of stress due to the increased needs and worse outcomes of work as they are shielding or self-isolating and may feel helpless and guilty. The psychological impact of the pandemic will be prolonged and varied. It is vital that Investigators increase understanding as much as possible to support NHS staff.
The aim of this survey is to examine the possible mental health burden on NHS staff as a result of the COVID-19 pandemic and how these change as the pandemic progresses. By understanding these effects, it will allow researchers to identify recommendations to allow support mechanisms to be put in place for NHS staff, to better manage this and future pandemics and similar crises.
Investigators are aiming to sample several cohorts of NHS staff including a subset of staff who are shielding. Staff will be asked to complete a series of online surveys at multiple timepoint: on study initiation, 1 month later and then 3 months after the pandemic has ceased in the UK. Additional timepoints may be added depending on the length and severity of the pandemic.
The main outcomes will be tracking changes in mental health measurements at the pre-defined timepoints. This work will allow Investigators to produce recommendations about the increased mental health support that NHS staff will need. If a need is demonstrated then an interventional research project will be designed and implemented.
Study Overview
Status
Conditions
Detailed Description
The aim of this survey is to examine the possible mental health burden on NHS staff as a results of the coronavirus COVID-19 pandemic and how these change as the pandemic progresses. By understanding these effects, it will allow Investigators to identify recommendations to allow appropriate support mechanisms to be put in place for NHS staff, to better manage this and future pandemics and similar crises.
Method:
Investigators aim to sample several cohorts of staff across the NHS. A subset of participants will include NHS staff that are currently shielding - they are self-isolating due to being identified as part of the at-risk/vulnerable members of society. The aim will be to survey a minimum of 100 members of staff. Introductory emails will be sent out to NHS staff using the hospital email system. Potential participants will be asked to read a participant information sheet and provide informed consent to participate in the subsequent survey.
Staff within the NHS will be asked to complete a series of surveys at multiple timepoints. The survey link will be circulated to staff with the introductory email. It will be sent at the following time points with a reminder to all on each occasion after 5 days: on study initiation, 1 month later and then 3 months after the pandemic has ceased in the UK. Additional timepoints may be added depending on the length and severity of the pandemic.
Qualtrics software will be used to host and administer the survey. The variables to be measured are:
Demographics (At first survey only): Age, sex, ethnic status, socio-economical status, religious identification and occupation.
Exposure to COVID-19 Mental health: The investigators will assess depression with 9 items (PHQ-9); anxiety with 7 items (GAD-7); paranoia (short Green paranoia scale), traumatic stress, somatic symptoms (PHQ-15); conspiracy mentality and social interactions (The loneliness scale).
Mediating psychological variables: Locus of control, death anxiety, 10 item Cognitive Reflection Task of analytical reasoning and personality traits 9 Big-five short version.
The surveys should take approximately 10 minutes to complete. Participants will be informed that should they feel distressed by the questions raised in the survey, that they should seek support from the providers in the introductory email. Participants will be able to withdraw from the study and any timepoint without providing a reason.
The participants anonymised data will be analysed by Professor Bentall's team at the University of Sheffield and stored on a secure, University server. The main outcomes of the study will be tracking changes in mental health measurements at the pre-defined timepoints.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Colette Mann
- Phone Number: 0114 226 5208
- Email: colette_mann@nhs.net
Study Contact Backup
- Name: Loretta Chantry-Groves
- Phone Number: 0114 226 5208
- Email: loretta.chantry-groves@nhs.net
Study Locations
-
-
-
Sheffield, United Kingdom, S10 1SJ
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants aged 16 years or over
- Participants must be working in the NHS
- NHS staff that are shielding will be eligible to participate
- NHS staff that are self-isolating will be eligible to participate
- Able and willing to provide informed consent
- Able to read and understand English
Exclusion Criteria:
• Participants will not be excluded on any other basis
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Depression
Time Frame: UP to 3 months after the pandemic ends in the UK
|
We will assess depression with 9 items (PHQ-9);
|
UP to 3 months after the pandemic ends in the UK
|
Changes in Anxiety
Time Frame: UP to 3 months after the pandemic ends in the UK
|
measured by GAD-7
|
UP to 3 months after the pandemic ends in the UK
|
Changes in feelings of paranoia
Time Frame: UP to 3 months after the pandemic ends in the UK
|
measured by the short Green paranoia scale
|
UP to 3 months after the pandemic ends in the UK
|
Traumatic Stress
Time Frame: UP to 3 months after the pandemic ends in the UK
|
As measured by PHQ-15
|
UP to 3 months after the pandemic ends in the UK
|
conspiracy mentality and social interactions
Time Frame: UP to 3 months after the pandemic ends in the UK
|
as measured by the loneliness scale
|
UP to 3 months after the pandemic ends in the UK
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Sarah Danson, Professor, Sheffield Teaching Hospitals NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STH21373
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece